Page 2 - Schering Plough Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Nuvalent Appoints Michael L Meyers, MD, PhD, to Board of Directors

/PRNewswire/ Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically.

New yorkUnited statesMemorial sloan kettering cancer centerUnited kingdomMichaell meyersJames porterNuvalent incPrnewswire nuvalent incMedicine at columbia presbyterian medical centerCompany quarterly report on formUs oncology medical affairsAlbert einstein college of medicineAventis pharmaceuticals incPlough research instituteExchange commissionSyndax pharmaceuticals inc

Nuvalent Inc (NUVL) Appoints Michael L Meyers to its Board

Nuvalent Inc (NUVL) Appoints Michael L Meyers to its Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesMemorial sloan kettering cancer centerMichaell meyersJames porterNuvalent incUs oncology medical affairsAlbert einstein college of medicineAventis pharmaceuticals incPlough research instituteSyndax pharmaceuticals incMedicine at columbia presbyterian medical centerSenior clinical advisorChief executive officerSenior vice presidentChief development officer

Biotheryx Announces Appointment of Tracy Lawhon as Chief Development Officer

/PRNewswire/ Biotheryx, Inc., a clinical stage company discovering and developing a portfolio of innovative small molecule targeted protein degraders (TPDs).

Philippe drouetTracy lawhonIndiana universityAdastra pharmaceuticals incIndiana university school of lawPlough research instituteClinical operations at valo health incCabrellis pharmaceuticalsPrnewswire biotheryx incStrategic developmentChief development officerChief executive officerVice presidentClinical operationsValo health incAdastra pharmaceuticals

Teva appoints Eric Hughes as head of R&D and Chief Medical Officer

Dr Eric Hughes will join Teva as Executive Vice President, Global R&D and Chief Medical Officer in August 2022.

United statesYale schoolNew jerseyHafrun fridriksdottirDerica hughesEric hughesBrian hughesBristol myers squibbVertex pharmaceuticalsYale school of medicineMerck research laboratoriesBristol myers squibb companyClinical research for hepatologyPlough research instituteTranslational medicine at vertex pharmaceuticalsYale university school of medicine

Teva Pharmaceutical names new member to exec team

Teva Pharmaceutical appointed Dr. Eric Hughes as executive vice president, global R&D and chief medical officer, effective Aug. 1.

Hafrun fridriksdottirEric hughesBristol myers squibbVertex pharmaceuticalsYale school of medicineMerck research laboratoriesPlough research instituteBristol myers squibb coCardiology exploratory clinical translational researchHepatology dermatology global development unit at novartisTeva pharmaceuticalDermatology global development unitSchering plough researchFibrotic diseasesGenetically defined diseasesCardiology exploratory clinical